Ronald G Sherrill from 3635 Melvin Dr S, Radisson, NY 13027, age 62

Us Patents

Oxoazepine Derivatives
view source
US Patent:

5889182, Mar 30, 1999
Filed:

Apr 14, 1997
Appl. No.:

8/817363
Inventors:

Milana Dezube - Chapel Hill NC
Gavin Charles Hirst - Marlboro MA
Ronald George Sherrill - Cary NC
Elizabeth Ellen Sugg - Durham NC
Jerzy Ryszard Szewczyk - Chapel Hill NC
Timothy Mark Willson - Durham NC
Assignee:

Glaxo Wellcome Inc. - Research Triangle Park NC
International Classification:

C07D22316
A61K 3153
US Classification:

540527
Abstract:

This invention relates to novel oxoazepine derivatives of Formula (I), R. sup. 1 R. sup. 2 NCOCH. sub. 2 N(R. sup. 3)COR. sup. 4 (I) to processes for their preparation, to pharmaceutical compositions containing them and to their use in medicine. More particularly, it relates to compounds which exhibit agonist activity for CCK-A receptors thereby enabling them to modulate the hormones gastrin and cholecystokinin (CCK) in mammals.

Sulfonamide Inhibitors Of Aspartyl Protease
view source
US Patent:

6613743, Sep 2, 2003
Filed:

Dec 6, 2000
Appl. No.:

09/731129
Inventors:

Michael Robin Hale - Bedford MA
Eric Steven Furfine - Durham NC
Ronald George Sherrill - Cary NC
Andrew Spaltenstein - Raleigh NC
Gregory Thomas Lowen - Williamsburg VA
Assignee:

Vertex Pharmaceuticals Incorporated - Cambridge MA
International Classification:

C07C30300
US Classification:

514 12, 514120, 514221, 51426338, 514274, 5142338, 514314, 514357, 514367, 514 38, 514387, 514403, 514452, 514456, 514465, 514471, 544168, 546169, 546355, 548163, 548164, 5483064, 5483077, 5483091, 5483112, 5483621, 5483625, 549220, 549366, 549372, 549396, 549414, 549464, 549475
Abstract:

The present invention relates to a novel class of sulfonamides of formula I which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of HIV aspartyl protease inhibitors characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting HIV-1 and HIV-2 protease activity and consequently, may be advantageously used as anti-viral agents against the HIV-1 and HIV-2 viruses. This invention also relates to methods for inhibiting the activity of HIV aspartyl protease using the compounds of this invention and methods for screening compounds for anti-HIV activity. The sulfonamides of formula I have the structure: wherein A, B, D, Dâ, E, G and R are as defined above.

Inhibitors Of Aspartyl Protease
view source
US Patent:

6617350, Sep 9, 2003
Filed:

Aug 9, 2001
Appl. No.:

09/927271
Inventors:

Michael R. Hale - Bedford MA
Christopher T. Baker - Waltham MA
Timothy A. Stammers - Etobicoke, CA
Ronald George Sherrill - Cary NC
Andrew Spaltenstein - Raleigh NC
Eric Steven Furfine - Durham NC
John Franklin Miller - Durham NC
Vicente Samano - Chapel Hill NC
Assignee:

Vertex Pharmaceuticals Incorporated - Cambridge MA
International Classification:

A61K 3134
US Classification:

514470, 549464, 549419, 549372, 514460, 514452
Abstract:

The present invention relates to a novel class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of HIV aspartyl protease inhibitors characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting HIV-1 and HIV-2 protease activity and consequently, may be advantageously used as anti-viral agents against the HIV-1 and HIV-2 viruses. This invention also relates to methods for inhibiting the activity of HIV aspartyl protease using the compounds of this invention and methods for screening compounds for anti-HIV activity.

Sulfonamide Inhibitors Of Aspartyl Protease
view source
US Patent:

7419967, Sep 2, 2008
Filed:

Aug 25, 2005
Appl. No.:

11/212045
Inventors:

Michael R Hale - Bedford MA, US
Eric S Furfine - Durham NC, US
Ronald G Sherrill - Cary NC, US
Andrew Spaltenstein - Raleigh NC, US
Gregory T Lowen - Williamsburg VA, US
Assignee:

Vertex Pharmaceuticals Incorporated - Cambridge MA
International Classification:

A61K 31/18
A61K 31/34
A61K 31/7072
US Classification:

514 49, 514 50, 514 86, 51421206, 51426338, 5142305, 514314, 514318, 514357, 514367, 514374, 514459, 514470, 514604
Abstract:

The present invention relates to a novel class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of HIV aspartyl protease inhibitors characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting HIV-1 and HIV-2 protease activity and consequently, may be advantageously used as anti-viral agents against the HIV-1 and HIV-2 viruses. This invention also relates to methods For inhibiting the activity of HIV aspartyl protease using the compounds of this invention and methods for screening compounds for anti-HIV activity.

Diazepine Compounds As Ligands Of The Melanocortin 1 And/Or 4 Receptors
view source
US Patent:

7442693, Oct 28, 2008
Filed:

May 27, 2005
Appl. No.:

11/569257
Inventors:

Jerzy Ryszard Szewczyk - Durham NC, US
Jason Daniel Speake - Durham NC, US
Douglas McCord Sammond - Carrboro NC, US
Ronald George Sherrill - Durham NC, US
Assignee:

SmithKline Beecham Corporation - Philadephia PA
International Classification:

C07D 401/14
C07D 403/06
C07D 403/14
A61K 31/551
A61P 3/04
US Classification:

514218, 540492
Abstract:

There is provided novel diazepines that function as agonists at the melanocortin 4 receptor and as agonists at the melanocortin 1 receptor, pharmaceutical compositions containing them, methods for their use in treatment, and processes for their preparation.

Inhibitors Of Aspartyl Protease
view source
US Patent:

7442718, Oct 28, 2008
Filed:

Jul 2, 2003
Appl. No.:

10/613650
Inventors:

Michael R Hale - Bedford MA, US
Christopher T Baker - Waltham MA, US
Timothy A Stammers - Etobicoke, CA
Ronald G Sherrill - Cary NC, US
Andrew Spaltenstein - Raleigh NC, US
Eric S Furfine - Durham NC, US
Francois Maltais - Somerville MA, US
John F Miller - Durham NC, US
Vicente Samano - Chapel Hill NC, US
Assignee:

Vertex Pharmaceuticals Incorporated - Cambridge MA
International Classification:

A61K 31/357
C07D 317/46
US Classification:

514466, 549438, 558390, 560 13, 560 17, 560 19, 560147, 560155, 514464, 514523, 514529
Abstract:

The present invention relates to a novel class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of HIV aspartyl protease inhibitors characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting HIV-1 and HIV-2 protease activity and consequently, may be advantageously used as anti-viral agents against the HIV-1 and HIV-2 viruses. This invention also relates to methods for inhibiting the activity of HIV aspartyl protease using the compounds of this invention and methods for screening compounds for anti-HIV activity.

Inhibitors Of Aspartyl Protease
view source
US Patent:

7919523, Apr 5, 2011
Filed:

Jul 2, 2008
Appl. No.:

12/217517
Inventors:

Michael R. Hale - Bedford MA, US
Christopher T. Baker - Waltham MA, US
Timothy A. Stammers - Etobicoke, CA
Ronald George Sherrill - Cary NC, US
Andrew Spaltenstein - Raleigh NC, US
Eric Steven Furfine - Durham NC, US
Francois Maltais - Somerville MA, US
John Franklin Miller - Durham NC, US
Vicente Samano - Chapel Hill NC, US
Assignee:

Vertex Pharmaceuticals, Inc. - Cambridge MA
International Classification:

A61K 31/357
C07D 319/06
US Classification:

514452, 549372, 549370
Abstract:

The present invention relates to a novel class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of HIV aspartyl protease inhibitors characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting HIV-1 and HIV-2 protease activity and consequently, may be advantageously used as anti-viral agents against the HIV-1 and HIV-2 viruses. This invention also relates to methods for inhibiting the activity of HIV aspartyl protease using the compounds of this invention and methods for screening compounds for anti-HIV activity.

Inhibitors Of Aspartyl Protease
view source
US Patent:

8455497, Jun 4, 2013
Filed:

Feb 12, 2009
Appl. No.:

12/370175
Inventors:

Michael R. Hale - Bedford MA, US
Roger Tung - San Diego CA, US
Stephen Price - Harlow, GB
Robin David Wilkes - West Hagbourne, GB
Wayne Carl Schairer - Westborough MA, US
Ashley Nicholas Jarvis - Primrose Hill, GB
Andrew Spaltenstein - Raleigh NC, US
Eric Steven Furfine - Croton on Hudson NY, US
Vicente Samano - Chapel Hill NC, US
Istvan Kaldor - Durham NC, US
John Franklin Miller - Durham NC, US
Michael Stephen Brieger - Greenwood IN, US
Ronald George Sherrill - Cary NC, US
Assignee:

Vertex Pharmaceuticals Incorporated - Cambridge MA
International Classification:

C07D 493/04
A61K 31/34
A61K 31/357
A61K 31/36
A61P 31/18
C07C 311/16
C07C 311/29
US Classification:

51425411, 514272, 514338, 514339, 514361, 514364, 514365, 514378, 514399, 514406, 514422, 514452, 514465, 514359, 544148, 544297, 544377, 5462717, 5462824, 5462837, 548127, 548131, 548159, 548204, 548247, 548249, 548256, 5483117, 5483644, 548526, 549 58, 549 60, 549366, 549435, 549464
Abstract:

The present invention relates to a novel class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of HIV aspartyl protease inhibitors characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting HIV-1 and HIV-2 protease activity and consequently, may be advantageously used as anti-viral agents against the HIV-1 and HIV-2 viruses. This invention also relates to methods for inhibiting the activity of HIV aspartyl protease using the compounds of this invention and methods for screening compounds for anti-HIV activity.